October 15th 2024
An analysis of 16 studies showed that CAR T-cell therapy is safe and effective for relapsed/refractory mantle cell lymphoma.
September 6th 2024
Magrolimab Plus Rituximab/Chemo Delivers Responses in Relapsed/Refractory DLBCL
February 3rd 2023At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.
FDA Approves Zanubrutinib for CLL/SLL
January 19th 2023The FDA has approved zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The prescribing label comes with warnings for hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.
Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL
January 11th 2023Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.
Second-Line Liso-Cel Continues to Improve Event-Free Survival in Large B-Cell Lymphoma
December 25th 2022In the second line setting, lisocabtagene maraleucel (liso-cel; Breyanzi) significantly reduced the risk of an event for patients with high-risk relapsed/refractory large B-cell lymphoma, compared with standard-of-care chemoimmunotherapy induction.
Brentuximab Vedotin Gets Green Light for High-Risk Hodgkin Lymphoma in Pediatric Patients
November 16th 2022The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients with classical Hodgkin lymphoma.
Adkins Discusses Benefit of Second-line CAR T-Cell Therapy in Large B-Cell Lymphoma
August 4th 2022Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.
Addition of Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression, Death in DLBCL
July 23rd 2022Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.
Axi-cel Linked To Longer Quality Time Without Toxicity in Patients With R/R LBCL
July 22nd 2022A quality time without symptoms of toxicities analysis of the pivotal ZUMA-7 trial found that patients with relapsed or refractory large B-cell lymphoma experienced longer time without toxicity with axicabtagene ciloleucel than with standard of care.
Mosunetuzumab Receives Priority Review Designation for Relapsed/Refractory Follicular Lymphoma
July 22nd 2022Mosunetuzumab, a CD20 and CD3 T-cell engaging bispecific antibody, received a priority review designation from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.
Zanubrutinib Significantly Improves PFS in Treatment-Naïve CLL/SLL Across Various High-Risk Subsets
July 21st 2022Patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, achieved superior progression-free survival with zanubrutinib vs a combination of bendamustine plus rituximab.
Oncology APPs, Research Nurses Are Uniquely Poised to Tackle irAE Management in Follicular Lymphoma
July 20th 2022Because immune-related adverse events can be hard to diagnose, patient education and clear avenues of communication with an oncology care team are critical, according to investigators at the 2022 Pan Pacific Lymphoma Conference.
Frontline Epcoritamab/R-CHOP Combination Induces 100% ORR in Patients With High-Risk DLBCL
June 26th 2022Data from the phase 1/2 EPCORE NHL-2 trial suggest that the combination of epcoritamab and R-CHOP is both effective and manageable in treating patients with high-risk diffuse large B-cell lymphoma.